10x Genomics (TXG) Q2 2026 Earnings Call Transcript
10x Genomics (TXG) reported Q2 2026 revenue of $151.0 million, up 3% YoY excluding non-recurring patent settlement revenue. Gross margin was 74%. FY2026 revenue guidance is $610 million to $630 million. Booked Atera orders exceed the 2026 shipment target of 40 units, with capacity as the constraint. Net loss was $17.9 million.
How this was made
The 30-second read
Why it matters
The key trading takeaway is the combination of raised FY guidance and strong Atera booked orders, offset by management’s expectation of a modest sequential Q3 revenue decline due to spatial product transition dynamics and a still-tenuous funding environment.
Market read
Raised FY guidance and Atera order momentum are fresh positives, but the expected Q3 sequential decline and capacity constraints create a clear near-term risk/reward setup for TXG.
What to watch
The guidance includes a small settlement component ($1.6M) and gross margin improvement partly reflects tariff refunds; traders may want to separate recurring platform momentum from one-time items.
Background
This is a Q2 2026 earnings call transcript for 10x Genomics, covering revenue, margins, segment performance, and FY 2026 guidance, with emphasis on the Atera platform transition.
Ticker impact
10x Genomics raised FY 2026 revenue guidance to $610M-$630M and said Atera booked orders already exceed the 2026 shipment target.
Likely bullish bias for near-term positioning, with volatility around Q3 transition and manufacturing-capacity commentary.
The article provides multiple new, decision-relevant datapoints: raised FY guidance, Atera booked orders vs shipment target, and explicit expectation of a sequential Q3 decline tied to customer moderation and transition dynamics.
Market effects
Reinforces AI-driven demand read-through for single-cell and spatial biology platforms, potentially supporting sentiment across genomics tools and consumables.
EMEA strength (up 15% YoY) and APAC softness (down 19% YoY) highlight uneven regional demand that could affect near-term channel inventory expectations.
If Atera pull-through estimates hold, it may shift investor focus toward platform transitions and high-throughput assay adoption globally.
Counterpoint
Atera order strength may not translate into near-term revenue if manufacturing capacity and customer transition behavior delay shipments and consumables pull-through.
Key entities
- company10x Genomics
TXG, reported Q2 2026 results and raised FY 2026 revenue guidance, highlighting Atera platform momentum and transition-driven Q3 softness.
- product_platformAtera
New spatial biology platform; management said booked orders exceed the 2026 shipment target and discussed pull-through expectations.
- product_platformXenium
Existing spatial platform; spatial consumables revenue growth was attributed to Xenium utilization.
- assayFlex Apex
High-throughput single-cell assay; cited as supporting reaction volume growth.
- serviceCatalyst Research Services
Service offering customers to process samples on Atera at 10x Genomics labs ahead of commercial availability.
